- Last edited on January 18, 2024
Differences
This shows you the differences between two versions of the page.
Both sides previous revision Previous revision | |||
mood:1-depression:geriatric [on November 14, 2023] psychdb [Vitamin B12 Deficiency] |
mood:1-depression:geriatric [on January 18, 2024] psychdb [Pharmacotherapy] |
||
---|---|---|---|
Line 114: | Line 114: | ||
<panel type="info" title="Pharmacotherapy for Geriatric Depression" subtitle="Lam, R. W. et al. (2017). Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression. The Canadian Journal of Psychiatry, 62(5), 353-354.*" no-body="true" footer="* = Note that the originally published CANMAT 2016 Guidelines 'Section 6. Special populations: Youth, women, and the elderly.' had several typographical errors and errata. This table references the corrected response letter with an updated table. See reference above for details."> | <panel type="info" title="Pharmacotherapy for Geriatric Depression" subtitle="Lam, R. W. et al. (2017). Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression. The Canadian Journal of Psychiatry, 62(5), 353-354.*" no-body="true" footer="* = Note that the originally published CANMAT 2016 Guidelines 'Section 6. Special populations: Youth, women, and the elderly.' had several typographical errors and errata. This table references the corrected response letter with an updated table. See reference above for details."> | ||
| **1st Step**\\ (use one or more agents in sequence) | **Monotherapy**: [[meds:antidepressants:snri:duloxetine|duloxetine]], [[meds:antidepressants:nassa:mirtazapine|mirtazapine]], [[meds:antidepressants:ssri:sertraline|sertraline]], [[meds:antidepressants:snri:venlafaxine|venlafaxine]], [[meds:antidepressants:serotonin-modulator:vortioxetine|vortioxetine]], [[meds:antidepressants:ssri:citalopram|citalopram]], [[meds:antidepressants:snri:v-desvenlafaxine|desvenlafaxine]], [[meds:antidepressants:ssri:escitalopram|escitalopram]] | | | **1st Step**\\ (use one or more agents in sequence) | **Monotherapy**: [[meds:antidepressants:snri:duloxetine|duloxetine]], [[meds:antidepressants:nassa:mirtazapine|mirtazapine]], [[meds:antidepressants:ssri:sertraline|sertraline]], [[meds:antidepressants:snri:venlafaxine|venlafaxine]], [[meds:antidepressants:serotonin-modulator:vortioxetine|vortioxetine]], [[meds:antidepressants:ssri:citalopram|citalopram]], [[meds:antidepressants:snri:v-desvenlafaxine|desvenlafaxine]], [[meds:antidepressants:ssri:escitalopram|escitalopram]] | | ||
- | | **2nd Step**\\ (if multiple 1st-step treatments are not effective or not indicated) | **Switch to:** [[meds:antidepressants:tca:nortriptyline|nortriptyline]], [[meds:antidepressants:ssri:fluoxetine|fluoxetine]], [[meds:antidepressants:maoi:moclobemide|moclobemide]], [[meds:antidepressants:ssri:paroxetine|paroxetine]], [[meds:antidepressants:maoi:phenelzine|phenelzine]], [[meds:antipsychotics:second-gen-atypical:6-quetiapine|quetiapine]], [[meds:antidepressants:sari:trazodone|trazodone]], [[meds:antidepressants:ndri:bupropion|bupropion]] \\ **Or combine with:** [[meds:antipsychotics:second-gen-atypical:3-aripiprazole|aripiprazole]],[([[https://www.nejm.org/doi/full/10.1056/NEJMoa2204462|Lenze, E. J., Mulsant, B. H., Roose, S. P., Lavretsky, H., Reynolds III, C. F., Blumberger, D. M., ... & Karp, J. F. (2023). Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression. New England Journal of Medicine.]])] [[meds:stimulants:2-methylphenidate:home|methylphenidate]], [[meds:mood-stabilizers-anticonvulsants:1-lithium|lithium]] | | + | | **2nd Step**\\ (if multiple 1st-step treatments are not effective or not indicated) | **Switch to:** [[meds:antidepressants:tca:nortriptyline|nortriptyline]], [[meds:antidepressants:ssri:fluoxetine|fluoxetine]], [[meds:antidepressants:maoi:moclobemide|moclobemide]], [[meds:antidepressants:ssri:paroxetine|paroxetine]], [[meds:antidepressants:maoi:phenelzine|phenelzine]], [[meds:antipsychotics:second-gen-atypical:6-quetiapine|quetiapine]], [[meds:antidepressants:sari:trazodone|trazodone]], [[meds:antidepressants:ndri:bupropion|bupropion]] \\ **Or combine with:** [[meds:antipsychotics:second-gen-atypical:3-aripiprazole|aripiprazole]] (2.5 to 15 mg)[([[https://www.nejm.org/doi/full/10.1056/NEJMoa2204462|Lenze, E. J., Mulsant, B. H., Roose, S. P., Lavretsky, H., Reynolds III, C. F., Blumberger, D. M., ... & Karp, J. F. (2023). Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression. New England Journal of Medicine.]])], [[meds:stimulants:2-methylphenidate:home|methylphenidate]], [[meds:mood-stabilizers-anticonvulsants:1-lithium|lithium]] | |
| **3rd Step**\\ (if multiple 1st- and 2nd-step treatments are not effective or not indicated) | **Switch to:** [[meds:antidepressants:tca:amitriptyline|amitriptyline]], [[meds:antidepressants:tca:imipramine|imipramine]]\\ **Or combine with:** an [[meds:antidepressants:ssri:home|SSRI]] or [[meds:antidepressants:snri:home|SNRI]] with [[meds:antidepressants:ndri:bupropion|bupropion]] | | | **3rd Step**\\ (if multiple 1st- and 2nd-step treatments are not effective or not indicated) | **Switch to:** [[meds:antidepressants:tca:amitriptyline|amitriptyline]], [[meds:antidepressants:tca:imipramine|imipramine]]\\ **Or combine with:** an [[meds:antidepressants:ssri:home|SSRI]] or [[meds:antidepressants:snri:home|SNRI]] with [[meds:antidepressants:ndri:bupropion|bupropion]] | | ||
</panel> | </panel> |